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Our aim was to investigate the natural evolution of cataplexy and polysomnographic features in untreated children with nar-
colepsy with cataplexy. To this end, clinical, polysomnographic, and cataplexy-video assessments were performed at diagnosis
(mean age of 10  3 and disease duration of 1  1 years) and after a median follow-up of 3 years from symptom onset (mean
age of 12  4 years) in 21 children with narcolepsy with cataplexy and hypocretin 1 deficiency (tested in 19 subjects).
Video assessment was also performed in two control groups matched for age and sex at first evaluation and follow-up and
was blindly scored for presence of hypotonic (negative) and active movements. Patients’ data at diagnosis and at follow-up were
contrasted, compared with controls, and related with age and disease duration. At diagnosis children with narcolepsy with
cataplexy showed an increase of sleep time during the 24 h; at follow-up sleep time and nocturnal sleep latency shortened,
in the absence of other polysomnographic or clinical (including body mass index) changes. Hypotonic phenomena and
selected facial movements decreased over time and, tested against disease duration and age, appeared as age-dependent. At
onset, childhood narcolepsy with cataplexy is characterized by an abrupt increase of total sleep over the 24 h, generalized
hypotonia and motor overactivity. With time, the picture of cataplexy evolves into classic presentation (i.e. brief muscle weak-
ness episodes triggered by emotions), whereas total sleep time across the 24 h decreases, returning to more age-appropriate
levels.
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Abbreviation: MSLT = multiple sleep latency test
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Introduction
Narcolepsy with cataplexy is a rare lifelong disorder characterized
by excessive daytime sleepiness, cataplexy, sleep paralysis, hallu-
cinations, and fragmented nocturnal sleep (American Academy of
Sleep Medicine, 2005). Narcolepsy with cataplexy usually arises in
adolescence or young adulthood (Dauvilliers et al., 2001), but the
diagnosis is typically established after a long period with a mean
delay across Europe from symptom onset to diagnosis of 14 years
(Luca et al., 2013). Narcolepsy with cataplexy is believed to have
a stable course, but longitudinal studies are scarce (Vignatelli
et al., 2011). The number of childhood diagnoses has recently
increased especially in some countries, probably because of
higher disease awareness, promoted in Italy by media campaigns
of the Italian Association of Narcoleptic patients (AIN onlus), and
also related to the awareness of narcolepsy in the context of the
possible association with H1N1 pandemic and vaccination (Han
et al., 2011; Partinen et al., 2012).
Cataplexy is the tell-tale symptom of narcolepsy with cataplexy
and is classically defined as a sudden loss of muscle tone evoked
by emotions (American Academy of Sleep Medicine, 2005). In
younger children closer to onset, it may co-occur with a complex
movement disorder with prominent facial involvement (Serra
et al., 2008), and persistent hypotonia. These abnormalities are
associated with ‘active’ movements (ranging from peri-oral to
frankly dyskinetic-dystonic movements even with stereotypies)
that increase during emotional stimulation (Plazzi et al., 2011).
The current study aimed to describe the natural evolution of this
symptomatology over time, together with other clinical and poly-
somnographic features. The lack of drugs specifically registered for
childhood narcolepsy with cataplexy and the concerns about treat-
ment safety led some parents to delay treatment for months or
years after diagnosis (Murali and Kotagal, 2006; Aran et al., 2010;
Lecendreux et al., 2012); in these cases we were able to docu-
ment the natural (i.e. without pharmacological treatment) disease
course.
Materials and methods
Subjects
We performed a prospective study including 21 of 87 patients with
narcolepsy with cataplexy under the age of 18, newly diagnosed be-
tween January 2001 and December 2012, whose parents refused
pharmacological treatment after diagnosis because of concerns about
possible side effects. The baseline clinical and polysomnographic fea-
tures of children included in the study were similar to those of children
with narcolepsy with cataplexy whose parents agreed to initiate
pharmacological treatment at the time of diagnosis. Behavioural stra-
tegies (scheduled naps) were systematically suggested to all patients
and families. All patients were regularly followed up at the Outpatient
Clinic for Narcolepsy of the University of Bologna, and underwent a
second hospitalization after at least 6 months from first evaluation and
before parents decided to start treatment. The study was performed
according to the Declaration of Helsinki and approved by local insti-
tutional review board; consent was obtained from parents and assent
from patients.
The study included the following systematic procedures conducted
at baseline (i.e. diagnosis) and at last follow-up evaluation: clinical
assessment, video recordings, and hospitalization with polysomno-
graphic recordings and blood samples for anti-streptolysin-O titres.
Clinical assessment
The same sleep medicine specialist (G.P.) systematically evaluated each
patient, monitoring onset and presence of symptoms (sleepiness, cata-
plexy, sleep paralysis, hypnagogic hallucinations, and disturbed noctur-
nal sleep). Subjective sleepiness was assessed by the Epworth
Sleepiness Scale modified for children (Murali and Kotagal, 2006).
Anthropometric measures (height, weight and body mass index)
were also collected. Body mass index percentiles were calculated ac-
cording to latest Italian normative values, and patients between the
85th and 97th percentiles or over the 97th percentile were classified as
overweight or obese, respectively (Cacciari et al., 2006).
Video recordings
Concurrent with each evaluation, video recordings were performed
with the subject sitting and/or standing for 30 min. This included
5 min of baseline recording (‘without stimulation’) and up to 25 min
while subjects were watching funny movies (‘under stimulation’).
Videos were subsequently scored by an independent blinded observer
(H.P.) for the occurrence of ‘negative’ (paroxysmal head drops and
falls, persistent eyelid narrowing and tongue protrusion, persistent
facial hypotonia, persistent generalized hypotonia) and ‘active’ (raising
of the eyebrows, perioral and tongue movements, facial grimaces,
swaying of the head or trunk, stereotyped motor behaviour, dyskinetic
or dystonic movements) motor phenomena using a purpose designed
score sheet. These ratings were performed separately for the ‘without
stimulation’ and ‘under stimulation’ conditions on an ordinal scale
ranging from 0 (absent) to 3 (continuously present). All single ‘nega-
tive’ and ‘active’ motor phenomena scores were summed to obtain
composite scores separately for the ‘without stimulation’ and ‘under
stimulation’ conditions. The presence or absence of two motor pat-
terns (neck extension viewing or puppet-like movements) during the
whole video recording was also evaluated. Two groups of healthy
controls, matched for age and sex with patients with narcolepsy
with cataplexy at baseline and at follow-up, underwent the same
video recording procedures, and anthropometric data collection.
Hospitalization
Within a month from first and last clinical assessment, patients were
hospitalized. They underwent 48 h of polysomnographic recordings
(24 h for adaptation and 24 h for diagnostic purposes) before a mul-
tiple sleep latency test (MSLT). MSLT was performed carefully instruct-
ing the children to lie down and close their eyes, and a parent was
allowed to stay in the laboratory room whenever requested by the
patient to avoid any fear of the unfamiliar environment. Sleep studies
were visually scored by a registered polysomnographic technician
(S.V.) who was blinded to clinical details. Total sleep time from the
second 24 h, sleep data from the second nocturnal recording, and
MSLT results were collected. Patients underwent lumbar puncture
for cerebrospinal hypocretin 1 assessment whenever possible, together
with blood samples for human leukocyte antigen (HLA) typing at first
hospitalization, and anti-streptolysin-O titres (first and follow-up
hospitalizations).
Categorical and continuous data were explored by means of fre-
quency and mean  standard deviation. Group comparisons (between
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subjects) were tested using Mann-Whitney or Chi-square tests. Within
subjects comparisons were assessed using Wilcoxon signed rank or
Chi-square tests, and variables showing a significant change over
time were tested against disease duration and age using linear regres-
sions. Pearson correlation coefficient analysis was used to study rela-
tionships between continuous variables.
Results
Clinical and biological assessment
Individual clinical data of the patients are reported in
Supplementary Table 1.
At baseline (mean 1  1 years from onset of narcolepsy with
cataplexy), patients with narcolepsy with cataplexy (71% males;
18 Caucasian, three Asian) were 10.0  3.2 years old. They pre-
sented with the following symptoms, presence (age at onset):
100% excessive daytime sleepiness (8.9  3.1 years old), 100%
cataplexy (9.1  3.1 years old), 19% sleep paralysis (8.3  3.5
years old), 57% hypnagogic hallucinations (8.7  3.3 years old),
and 48% disturbed nocturnal sleep (8.9  3.4 years old). Mean
modified Epworth Sleepiness Scale score was 13.7  3.3. Mean
weight and height were 46.4  22.2 kg and 1.4  0.2 m, with a
corresponding mean body mass index of 22.5  5.1 kg/m2 (range
15.8–32.2 kg/m2). According to Italian reference values, eight
(38%) patients were overweight and six (29%) were obese.
Additionally, three (14%) children had precocious puberty and
13 (62%) had behavioural alterations (i.e. aggressive behaviour
or irritability reported by patients). Nineteen of 21 (90.5%) pa-
tients were HLA-DQB1*06:02-positive. All 19 tested patients were
hypocretin 1-deficient (all patients were under the diagnostic cut-
off 110 pg/ml, and 13 of 19 below 40 pg/ml that can be con-
sidered a safe detection limit across different assays), including
two HLA-DQB1*06:02-negative subjects. Two patients underwent
hypocretin 1 assay twice, after 4 months and 1.5 years
from symptoms onset, and after 11 months and 2 years from
symptoms onset, respectively (all measurements were 540 pg/
ml). Mean anti-streptolysin-O titres were 320.3  250.7 IU/ml,
with 14 patients (67%) being over 400 IU/ml.
At follow-up assessment, performed 3.1  1.9 years from the
onset of narcolepsy with cataplexy and 2.1  1.7 years (range
0.5–5.2) from first observation, patients had a mean age of
12.1  3.9 years. Compared to baseline, we found a non-signifi-
cant increase in the occurrence of sleep paralysis (24%, age at
onset of 9.2  3.4 years old), hypnagogic hallucinations (67%,
age at onset of 8.8  3.0 years old), and disturbed nocturnal
sleep (62%, age at onset of 10.0  4.0 years old). Modified
Epworth Sleepiness Scale was stable over time (mean of
13.5  4.6, P = 0.47). Over the follow-up period, children grew
up to mean weight of 50.0  22.2 kg (P = 0.1), height of
1.5  0.2 m (P = 0.007), and body mass index of 23.4  5.1
(range 16.3–32.1, P = 0.5). According to normative data, four
(20%) and six (29%) patients were overweight and obese, re-
spectively, a slight decrease from baseline. Decreased ratio of ab-
normal to normal body mass index, however, did not reach the
statistical significance. Mean anti-streptolysin-O titres were stable
(P = 0.8) showing mean values of 375.6  282.1 IU/ml at follow-
up, and the decreased ratio over time of patients 4400 IU/ml
(n = 8, 40%) did not reach statistical significance (P = 0.66).
Polysomnograhic data
Polysomnographic data at baseline and at follow-up assessment
are reported in Table 1. Nocturnal sleep features were stable over
time, apart from a significant shortening of sleep latency.
Daytime sleep propensity and the number of sleep onset REM
periods at the MSLT were also stable, whereas the 24 h total sleep
time decreased from first to follow-up evaluation (P = 0.004,
Fig. 1) as the final result of the (non-significant) decreases of
daytime and night-time sleep.
Video recordings of cataplexy: negative
and active motor phenomena
Table 2 shows anthropometric data and the single and composite
scores of ‘negative’ and ‘active’ motor phenomena of patients
with narcolepsy with cataplexy in parallel with healthy controls
at baseline and follow-up evaluation.
At first evaluation, patients with narcolepsy with cataplexy had
higher scores for all ‘negative’ and ‘active’ scores compared with
controls, except peri-oral and tongue movements and facial grim-
aces in the ‘without stimulation’ condition. None of the patients
displayed myoclonic jerks. Patients with narcolepsy with cataplexy
were also more likely to have the two motor patterns we assessed
(‘neck extension viewing’ and ‘puppet-like’ movements) compared
with controls. All composite scores of ‘negative’ and ‘active’
movements were higher in patients than controls.
At follow-up evaluation, patients with narcolepsy with cataplexy
had higher scores of all ‘negative’ motor phenomena than control
subjects, except head drops and generalized hypotonia in the
‘without stimulation’ condition, meaning that this sort of spontan-
eous cataplexy disappears along the disease course. Narcolepsy
with cataplexy patients displayed higher scores for all ‘active’ phe-
nomena in the ‘under stimulation’ condition, except facial grim-
aces, together with higher scores of head and trunk swaying and
stereotypies in the ‘without stimulation’ condition than healthy
controls. In two patients, a myoclonic jaw sagging in the ‘under
stimulation’ condition was also observed. Patients with narcolepsy
with cataplexy also had more frequent motor pattern neck exten-
sion viewing than controls. All composite scores of ‘negative’ and
‘active’ movements were higher in patients than controls.
The within subjects comparison of patients with narcolepsy with
cataplexy patients at baseline versus follow-up evaluation dis-
closed a significant decrease of all single and composite ‘negative’
scores (Fig. 1). Moreover, 2 of 21 (9.5%) and 15 of 21 (71.4%)
did not show any hypotonic phenomenon (i.e. negative composite
score = 0) in the ‘without stimulation’ condition at first and follow-
up assessments, respectively. Conversely, only three single active
motor phenomena occurring ‘under stimulation’ (eyebrows raising,
facial grimaces, and head and trunk swaying) significantly
decreased over time leading to a non-significant reduction of the
active composite scores.
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Relation between age, disease duration
and evolving picture of childhood
narcolepsy with cataplexy
We further tested disease duration and age as predictors of 24 h
total sleep time and of the composite scores of negative motor
phenomena in the without stimulation and under stimulation con-
ditions, using linear regressions (Fig. 2).
Age (beta = 0.237, P = 0.171) and disease duration
(beta = 0.255, P = 0.139) were not significant predictors of
24 h total sleep time.
Age (beta = 0.460, P = 0.002; and beta = 0.461,
P5 0.0005) and disease duration (beta = 0.360, P = 0.019;
and beta = 0.552, P5 0.0005) were inversely correlated with
negative motor phenomena score in the ‘without stimulation’
and ‘under stimulation’ conditions when tested separately. At
multivariate analyses, age maintained a significant influence
(beta = 0.387, P = 0.039; and beta = 0.512, P = 0.002),
whereas disease duration lost significance (beta = 0.117,
P = 0.523; and beta = 0.232, P = 0.135) in both conditions.
Relation between motor phenomena
and biochemical evidence of strepto-
coccal infection
Supplementary Table 2 shows the scores of negative and active
motor phenomena of patients with narcolepsy with cataplexy with
and without elevated anti-streptolysin-O titres (4400 IU/ml) at
baseline and follow-up evaluations.
At baseline, there were no statistically significant differences in
negative scores, but only significantly higher scores of single active
phenomena (facial grimaces under stimulation, and stereotyped
motor behaviour in both without stimulation and under
stimulation conditions). The comparison of composite scores did
not reach statistical significance, however, active composite scores
were significantly correlated with anti-streptolysin-O titres in both
the ‘without stimulation’ (Pearson coefficient = 0.525; P = 0.017)
and ‘under stimulation’ (Pearson coefficient = 0.530; P = 0.020)
conditions.
At follow-up evaluation, the eight patients with elevated anti-
streptolysin-O titres did not differ from the others, and there were
no significant relationships between composite scores and anti-
streptolysin-O titres.
Discussion
We report for the first time that, in untreated patients, the picture
of childhood cataplexy, characterized by a complex movement
disorder with persistent hypotonia and prominent facial involve-
ment, gradually turns into the classically reported adult phenotype.
In the latter, cataplexy is only characterized by paroxysmal epi-
sodes of loss of antigravitary muscle tone exclusively evoked by
emotions with normal interictal neurological examination. We also
found high 24 h total sleep time close to onset that subsequently
shortened over time. The study suggests that acute removal of
hypocretin 1 signalling induces a true hypersomnia associated
with generalized decrease of muscle tone that subsequently
evolves over time.
Monitoring disease evolution in 21 drug naive cases over a
mean follow-up period of 2 years (3 years from disease onset),
we found that: (i) subjective and objective (MSLT) daytime sleepi-
ness, and increased body mass index abruptly appeared at narco-
lepsy with cataplexy onset and remained stable over time; (ii)
sleep amounts across the 24 h peaked close to onset and then
shortened together with nocturnal sleep latency; (iii) cataplexy
severity, as reflected by both hypotonic motor phenomena and
Table 1 Polysomnographic and MSLT data of patients with narcolepsy with cataplexy at baseline and follow-up
hospitalizations with statistical comparison
Baseline Follow-up Wilcoxon test
Mean SD Mean SD P-Value
PSG nocturnal sleep latency 5.35 2.86 2.99 2.59 0.0185
PSG nocturnal total sleep time 503.86 105.17 454.33 94.48 n.s.
PSG nocturnal sleep efficiency 86.92 11.38 84.64 10.43 n.s.
PSG nocturnal arousal index 16.69 4.84 15.94 4.27 n.s.
PSG sleep stages shift index 9.84 3.05 10.53 3.37 n.s.
PSG nocturnal REM latency 15.36 24.54 57.25 111.16 n.s.
PSG nocturnal time spent in non-REM stage 1 (%) 12.51 5.15 12.92 8.12 n.s.
PSG nocturnal time spent in non-REM stage 2 (%) 41.39 6.58 42.69 9.49 n.s.
PSG nocturnal time spent in slow wave sleep (%) 23.02 8.12 23.74 7.85 n.s.
PSG nocturnal time spent in REM sleep (%) 23.10 6.35 20.66 7.81 n.s.
PSG nocturnal number of sleep cycles 4.90 1.26 4.10 1.52 n.s.
PSG Daytime total sleep time 130.41 84.12 94.44 61.77 n.s.
PSG 24 hours total sleep time 630.45 72.72 551.56 128.77 0.004
MSLT mean sleep latency 4.19 3.15 3.96 3.27 n.s.
MSLT number of sleep onset REM periods 3.80 1.01 4.25 0.85 n.s.
n.s. = non-significant; PSG = continous polysomnography.
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‘active’ movements (mainly the facial movements under stimula-
tion), decreased over time; (iv) hypotonic features of cataplexy
were age dependent; and (v) biochemical evidence of streptococ-
cal infection correlated with motor overactivity only close to dis-
ease onset.
Therefore narcolepsy with cataplexy is not a stable phenotype in
children, but displays a characteristic evolution with an abrupt
onset followed by an improvement over time. Parents of children
with narcolepsy with cataplexy usually report a sudden change in
sleep–wake habits at first that can often be timed to a particular
day. This consists of a voluntary anticipation of bedtime with
increased time spent in bed, occurrence of disturbing awakenings
and dreaming, and prolonged daytime naps (sometimes lasting
hours) with difficulty awakening as in our case series and in a
previous clinical observation (Kotagal et al., 1990). Behavioural
changes such as irritability also appear (Guilleminault and Pelayo,
1998; Partinen et al., 2012). Hypotonia with prominent facial in-
volvement (mouth opening and tongue protrusion), a global
floppy aspect, and gait disturbance with falls to the ground can
occur without apparent relation to emotions (Serra et al., 2008;
Plazzi et al., 2011). Over the next few weeks children most often
gain weight, either searching for sweet foods with increased ap-
petite or without changing eating habits (Poli et al., 2013).
Misdiagnoses at this time are frequent because the phenotype is
different from adult narcolepsy with cataplexy characterized by
brief, refreshing sleep attacks, and episodes of weakness evoked
by strong emotions.
As suggested by a previous study in childhood NC (Plazzi et al.,
2011), where hypotonic phenomena inversely correlated with age
and time from narcolepsy with cataplexy onset, hypotonia symp-
toms gradually decreased over time leading to the disappearance
of ‘spontaneous’ cataplexy, namely head drops and falls without
recognizable emotional stimulation (e.g. while walking or eating),
and the appearance of classical cataplexy. Accordingly, in our
series the ‘adult’ cataplexy phenotype (i.e. no evidence of hypo-
tonia without emotional stimulation) was present in 9.5% and
71.4% of children at first and follow-up evaluation, respectively.
What could explain the evolution of cataplexy over time? At first,
muscle atonia could reflect the widespread effect of the acute
failure of hypocretinergic transmission that facilitates motor
neuron activity in the brainstem and spinal cord (Yamuy et al.,
2004; Mascaro et al., 2009; Schreyer et al., 2009). Compensatory
mechanisms then likely occur within the CNS, despite stable low
hypocretin 1 levels, as shown here in some patients. The re-emer-
gence of transient episodes of atonia only during emotions could
reflect the engagement of yet unknown compensatory mechan-
isms during emotional processing. Accordingly, functional studies
in patients with narcolepsy with cataplexy showed altered emo-
tional processing by cortical-subcortical structures influenced by
disease duration (Schwartz et al., 2008; Ponz et al., 2010).
Similarly to our childhood cases, spontaneous joint buckling with
falls followed by clinical amelioration over 2 years has been re-
cently described in an equine model of familial narcolepsy with
cataplexy (Ludvikova et al., 2012).
In previous observations, we have reported that childhood cata-
plexy is not characterized solely by peculiar hypotonic features,
but also includes motor overactivity compared with control
subjects. Some of these hyperkinetic features, such as choreic
movements, were reminiscent of brain paediatric autoimmune
post-streptococcal diseases and correlated with anti-streptolysin-
O titres (Plazzi et al., 2011). These hyperkinetic movements
should not be confused with the myoclonic features of cataplexy
that have been documented in polygraphic studies in adults
(Rubboli et al., 2000; Vetrugno et al., 2010), subjectively reported
by patients (Overeem et al., 2011), and observed in our case
series only at follow-up. The similarities between PANDAS
(Paediatric Autoimmune Neuropsychiatric Disorders Associated
with Streptococcal infections), Sydenham’s Chorea and childhood
narcolepsy phenotypes include a partial remission over time and
an association with biochemical evidence of past streptococcal
infection (Dale, 2005; Aran et al., 2009). The non-significant
decrease of anti-streptolysin-O over time that may be influenced
by insufficient follow-up time given the evidence of higher
Figure 1 Individual 24 h total sleep time, negative motor phe-
nomena scores without and with stimulation at baseline and at
follow-up evaluations.
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anti-streptolysin-O in patients closer to narcolepsy with cataplexy
onset (Aran et al., 2009), and by the limited number of patients in
our series and by the relatively frequent occurrence of strepto-
coccal infections in the paediatric population. Conversely, the
enhancement of these active motor phenomena during emo-
tional stimulation suggests a relation with genuine cataplexy
and thus a distinct pathophysiological role of hypocretinergic
interactions.
Figure 2 Scattered graphs of age (left column) and disease duration (right column) versus 24 h total sleep time (top row), negative motor
phenomena score ‘without stimulation’ (middle row) and ‘under stimulation’ (bottom row).
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The pathogenesis of sporadic narcolepsy with cataplexy is likely
autoimmune with hypocretin neurons being a target (Kornum
et al., 2011a), and possibly interacting with other neurotransmis-
sion systems during development (Sundvik et al., 2011).
Narcolepsy with cataplexy is strongly associated with HLA–
DQB1*06:02 (Mignot et al., 1994), an effect also modulated by
the presence of other HLA subtypes (Mignot et al., 2001; Hor
et al., 2010), and by polymorphisms in the T cell receptor alpha
(Hallmayer et al., 2009; Hor et al., 2010), P2YR11 receptor and
other loci (Kornum et al., 2011b; Faraco et al., 2013). Clinical and
biochemical evidence temporally links the onset of narcolepsy with
cataplexy symptoms with an activation of the immune system by
infection, either bacterial such as streptococcal (Aran et al., 2009),
or viral such as H1N1 flu or vaccination (Han et al., 2011; Partinen
et al., 2012), or with an autoimmune response proved by produc-
tion of self-targeted antibodies (Cvetkovic-Lopes et al., 2010;
Kawashima et al., 2010). We speculate that the clinical evolution
of childhood narcolepsy with cataplexy resembles the course of
autoimmune disorders that show a partial remission after an
abrupt acute onset phase (Wingerchuk et al., 1999; von Herrath
et al., 2007). Further studies of the narcolepsy with cataplexy
course are warranted to disentangle whether adaptive compensa-
tory mechanisms or a partial spontaneous remission drive alone, or
in combination, our clinical observations.
Our main finding of extended sleep time across the 24 h close
to onset fits well with past clinical observations of prolonged,
unrefreshing naps in children with narcolepsy with cataplexy
(Kotagal et al., 1990), and with our clinical impression from par-
ents’ reports. Although adult patients with narcolepsy with cata-
plexy show an amount of sleep over the 24 h comparable to Tafti
et al. (1992), or higher than Broughton et al. (1988), healthy
control subjects, children with narcolepsy with cataplexy displayed
an acutely increased need to sleep in the 24 h at disease onset that
subsequently stabilized at lower levels. While acknowledging a
potential influence of age, we emphasize the absence of prospect-
ive studies on sleep across the 24 h, and that the life-span
explored here was not large enough to impact on the MSLT, as
documented in patients with narcolepsy with cataplexy of differ-
ent age groups (Dauvilliers et al., 2004). Despite the absence of
normative MSLT data in children, in our case series MSLT proved
to be a useful and reliable diagnostic tool, with all patients at both
evaluations having two or more sleep onset REM periods, but one
and two patients showing a mean sleep latency 48 min at first
and follow-up evaluations, respectively, as expected (Vendrame
et al., 2008).
Follow-up clinical assessments revealed a non-significant in-
crease in the report of first occurring sleep paralysis, hypnagogic
hallucinations, and disturbed nocturnal sleep together with body
mass index shifting to lower percentiles. Acknowledging that dis-
tinguishing hypnagogic hallucinations from dream experiences can
be difficult in children (Guilleminault and Pelayo, 1998), we
cannot exclude that, over time, the full-blown narcolepsy with
cataplexy symptom tetrad may develop (Dauvilliers et al., 2004;
Ohayon et al., 2005). High obesity prevalence has been reported
in both adults and children with narcolepsy with cataplexy in
cross-sectional studies (Poli et al., 2009, 2013). Body mass index
abruptly peaked at onset (Poli et al., 2013), and subsequently
decreased without reaching normality in our series, thus the
weight of patients with narcolepsy with cataplexy seems to stabil-
ize above population values.
Our study also has limitations. We used video recordings
without any additional neurophysiological measurement, thus pre-
venting us from providing measurement of a definite electromyo-
graphic pattern and the precise muscles involved in the cataplectic
attack. However, the prominent facial involvement in younger pa-
tients fits well with polygraphic cataplexy characterizations that
suggested a grossly rostro-caudal progression of muscle atonia in
adults (Rubboli et al., 2000; Vetrugno et al., 2010) confirmed by
the self-reported highest involvement of the facial district
(Overeem et al., 2011). Moreover, our semi-standardized setting
with a single recording lasting 30 min does not allow us to com-
ment on the temporal evolution of the described motor phenom-
ena (e.g. progressive increase or habituation), but in our opinion
was appropriate to describe cataplexy features in the absence of
any available standardized test.
The abrupt onset of childhood narcolepsy with cataplexy, the
acute movement disorder, the sudden weight gain and the hyper-
somnolence represent a unique and vanishing clinical framework
that partially remits over time. On one hand, this can explain the
diagnostic challenges and the diagnostic delay (namely, patients
are more easily diagnosed once narcolepsy with cataplexy turns to
the classical picture); on the other hand, the changes of symptoms
can reassure parents about the prognosis of these early onset
cases, but also claims for caution in interpreting results of uncon-
trolled therapeutical studies.
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